NCT03930953 2026-02-19
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Celgene
Phase 1/2 Active not recruiting
Clinical Trials
7 trialsNCT04809467 2026-02-04
topMIND
Incyte Corporation
Phase 1/2 Terminated
NCT05222555 2026-01-16
MINDway
Incyte Corporation
Phase 1/2 Active not recruiting
NCT04661007 2025-12-18
J-MIND
Incyte Corporation
Phase 1/2 Active not recruiting
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT05205252 2023-08-15
ARIA
Ipsen
Phase 1/2 Withdrawn
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn